Summary of Biomarker Analysis
Method of Measurement
Biomarker Measured
Biomarker Categories
Summary completed October 2019
Biomarkers for Alzheimer’s Disease
BiomarkerAltoida |
Biomarker MeasuredDigital |
Method of MeasurementAmyloid, Eye movement |
UseDiagnostic, Monitoring, Pharmacodynamic/response, Prognostic, Susceptibility/risk, Predictive |
Stage of DevelopmentIn use (FDA approved) |
BiomarkerMulti-modal Neuroimaging |
Biomarker MeasuredBlood/Plasma, Imaging, CSF |
Method of MeasurementAmyloid |
UseDiagnostic, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerPlasma putative biomarkers (i.e. Ab40 amyloid and total Ab42 amyloid, free, bound, free/bound, truncated, sAPPα) (BALTAZAR) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementAmyloid |
UseDiagnostic, Prognostic, Predictive |
Stage of DevelopmentClinical trials |
BiomarkerFatty acid binding protein 3 (FABP3) |
Biomarker MeasuredCSF |
Method of MeasurementNeuronal damage |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerEye Tracking in Reading (ADAL) |
Biomarker MeasuredOptical |
Method of MeasurementEye movement |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerFlorbetapir F18 AV45 F18 |
Biomarker MeasuredImaging |
Method of MeasurementAmyloid |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerFlorbetaben (FBB ACC) |
Biomarker MeasuredImaging |
Method of MeasurementAmyloid |
UseUnknown |
Stage of DevelopmentClinical trials |
BiomarkerFerritin |
Biomarker MeasuredImaging, CSF |
Method of MeasurementBrain iron levels |
UseMonitoring, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerFlortaucipir (AV1451) |
Biomarker MeasuredImaging |
Method of MeasurementTau |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerInterleukin 1β (IL- 1β) (plasma) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementInflammation |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerImaging Inflammation |
Biomarker MeasuredImaging, CSF |
Method of MeasurementInflammation |
UsePrognostic |
Stage of DevelopmentClinical trials |
BiomarkerhFABP |
Biomarker MeasuredCSF |
Method of MeasurementNeuronal damage |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerEye movement and Retinal nerve fiber layer thickness (BEAM) (Pittsburgh Compound B [11C]-PIB) |
Biomarker MeasuredOptical |
Method of MeasurementVasculature |
UsePharmacodynamic/response, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerEye Movement Recording (MOMAD) |
Biomarker MeasuredOptical |
Method of MeasurementEye movement |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerInterleukin 6 (IL-6) (plasma) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementInflammation |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerInterleukin 10 (IL-10) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementInflammation |
UseSusceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerMagnetoencephalography (MEG) |
Biomarker MeasuredImaging |
Method of MeasurementCell signaling |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerMCP-1 |
Biomarker MeasuredCSF |
Method of MeasurementInflammation |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerMetabolic Hyperspectral Retinal Camera (MHRC) |
Biomarker MeasuredOptical |
Method of MeasurementAmyloid |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerEpileptiform Activity During REM Sleep |
Biomarker MeasuredBlood/Plasma, Imaging |
Method of MeasurementCell signaling |
UseDiagnostic |
Stage of DevelopmentClinical trials |
Questions? Additional biomarkers to share? Contact Us